Montrouge, France, October 27 (10:30 p.m. CET)
DBV Technologies presents its financial results for the third quarter of 2023 and provides an update on its activities
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and live audio webcast on Tuesday, October 31, 2023 at 11:00 p.m. (CEST) in order to present the financial results for the third quarter of 2023 and to provide an update on its activities.
Participants can access this event via the teleconference numbers below and by requesting to join the DBV Technologies call:
United States: 1-844-481-2866
International: 1-412-317-1859
The call will be broadcast live on the company’s website, in the “Investors and Press” section: https://www.dbv-technologies.com/fr/investor-relations/. A replay of the presentation will also be available on the DBV website after the event.
About DBV Technologies
DBV Technologies is developing Viaskin™, a proprietary experimental technology platform with broad potential applications in immunotherapy. Viaskin™ uses epicutaneous immunotherapy, or EPIT™, which is the method developed by DBV to deliver biologically active compounds to the immune system through intact skin. With this new category of non-invasive product candidates, the Company is working to safely transform the care of patients suffering from food allergies. DBV Technologies’ food allergy programs include ongoing clinical trials of Viaskin™ Peanut. DBV Technologies has global headquarters in Montrouge (France) and a North American operational structure in Basking Ridge, New Jersey. The Company’s ordinary shares are traded on segment B of Euronext Paris (ticker: DBV, ISIN Code: FR0010417345), while the Company’s ADSs (each representing half of an ordinary share) are traded on Nasdaq. Global Select Market (ticker: DBVT).
Investor contact
Katie Matthews
DBV Technologies
+1 857-529-2363
[email protected]
Media contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
Attachment